Europeiska unionen - svenska - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinibmaleat - agenter för dermatit, med undantag av kortikosteroider - hundar - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 och 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - carcinom, non-small cell lung - antineoplastiska medel - zykadia är indicerat för behandling av vuxna patienter med anaplastisk lymfomkinas (alk) positiv, avancerad, icke-småcellad lungcancer (nsclc) som tidigare behandlats med crizotinib.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer limited - tofacitinib - artrit, reumatoid - immunsuppressiva - behandling av reumatoid artrit.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Europeiska unionen - svenska - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - flukonazol - pulver till oral suspension - 10 mg/ml - natriumbensoat hjälpämne; flukonazol 10 mg aktiv substans; sackaros hjälpämne - flukonazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

omnia läkemedel ab - flukonazol - pulver till oral suspension - 10 mg/ml - sackaros hjälpämne; natriumbensoat hjälpämne; flukonazol 10 mg aktiv substans - flukonazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

omnia läkemedel ab - flukonazol - pulver till oral suspension - 10 mg/ml - sackaros hjälpämne; natriumbensoat hjälpämne; flukonazol 10 mg aktiv substans - flukonazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

omnia läkemedel ab - flukonazol - pulver till oral suspension - 10 mg/ml - flukonazol 10 mg aktiv substans; sackaros hjälpämne; natriumbensoat hjälpämne - flukonazol